HTRF MDM2 Binding Kit, 500 Assay Points

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

HTRF MDM2 Binding Kit, 500 Assay Points

The MDM2 binding assay is designed to screen and characterize compounds that specifically bind to the E3 ligase, MDM2.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

View product information

Feature	Specification
Application	Protein-Protein Interaction
Sample Volume	5 µL

Request More Information

The MDM2 binding assay is designed to screen and characterize compounds that specifically bind to the E3 ligase, MDM2.

View product information

Product Variants

Unit Size: 500 Assay Points

Part #:

64BDMDM2PEG

List Price

USD 1,252.00

Unit Size: 10,000 Assay Points

Part #:

64BDMDM2PEH

List Price

USD 15,010.00

Product information

Overview

A fast and easy way to identify new binders to MDM2 protein.

MDM2, also known as murine double minute 2, is involved in many biological processes and is closely associated with DNA repair, cell cycle arrest, apoptosis, and the occurrence of many diseases. MDM2 is one of the most popular E3 ligases which is recruited by bifunctional Proteolysis-targeting chimeras (PROTACs) to induce ubiquitination and subsequent proteasomal degradation of a targeted protein. MDM2 interacts with several proteins to form the functional E3 ubiquitin ligase complex, in which MDM2 functions as a substrate receptor of the E3 ubiquitin ligase complex and targets various proteins to proteolysis.

Therefore, identifying new PROTAC MDM2 ligands can improve selective proteasomal-dependent degradation of proteins of interest, involved in disease onset such as cancers, neurodegenerative, and metabolic disorders.

Specifications

Other Specifications

Application	Protein-Protein Interaction
Automation Compatible	Yes
Brand	HTRF
Detection Modality	HTRF
Product Group	Kit
Sample Volume	5 µL
Shipping Conditions	Shipped in Dry Ice
Target Class	Binding Assay
Technology	TR-FRET
Therapeutic Area	Inflammation Neuroscience Oncology & Inflammation
Unit Size	500 Assay Points

Video gallery

How it works

Assay principle

The HTRF MDM2 Binding Kit is a competitive assay format which uses MI-1061 Red Ligand as MDM2 ligand, a GST tagged human MDM2 protein, and an anti GST Europium Cryptate-labeled antibody. MDM binding compounds compete with the HTRF MI-1061 Red Ligand and thereby prevent FRET from occurring.

Assay protocol

The MDM2 binding assay can be run in a 96- or 384-well low volume white plate (20 µL final). As described here, samples or standards are dispensed directly into the assay plateT the MDM2 GST-tagged protein is then added, followed by the dispensing of the HTRF reagents: the anti GST antibody labeled with Europium cryptate and the MI-1061 Ligand labeled with a Red HTRF acceptor. The reagents labeled with HTRF fluorophores may be pre-mixed and added in a single dispensing step. No washing steps are needed. The protocol can be further miniaturized or upscaled by simply resizing each addition volume proportionally.

Assay validation

Screening of MDM2 orthosteric ligands

A panel of MDM2 ligands were characterized. AMG-232 (assay standard), Nutlin-3a and MI-773 display the expected potency and pharmacological ranking in good correlation with the literature. An irrelevant compound Lenalidomide (Cereblon ligand) did not compete with the MI-1061 Red-Ligand binding, demonstrating the specificity of the HTRF MDM2 Binding Kit.

Screening of PROTAC compounds (MDM2-ligand based)

Two MDM2-ligand based PROTAC compounds (MD-224 and A-1874) were characterized. Both compound display the right potency in good correlation with the literature.

DMSO effect on assay performance

Different percentages of DMSO were tested, from 0.4% to 2% (final in the wells). The results indicate that the assay window is reduced with the increasing percentages of DMSO, while the pharmacology remains stable.